Karyopharm Therapeutics | KPTI - Cash And Equivalent


Karyopharm Therapeutics reported $60.54M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Abbott USD 8.52B 1.01B Dec/2025
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
BioCryst Pharmaceuticals USD 335.91M 251.83M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
J&J USD 19.71B 1.48B Dec/2025
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
MacroGenics USD 57.22M 22.91M Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Takeda JPY 654.94B 26.55B Dec/2025
Tectonic Therapeutic USD 253.8M 14.64M Dec/2025
TG Therapeutics USD 199.51M 21.2M Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Xencor USD 54.07M 25.78M Dec/2025